Sign inJoin waitlistJoin the waitlist

Enrica Marchi

Clinical Director, T-Cell Lymphoma Center · Dana-Farber Cancer Institute

Credentials: · · · · · · · ·

History

T-Cell Lymphoma Center · Dana-Farber Cancer Institute
Present
Harvard Medical School
Present

Columbia University, New York Presbyterian Hospital
Lincoln Medical Center
University of Bologna

Research

Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma
Journal of Clinical Oncology · 2007 · 222 citations
Combined oral 5-azacytidine and romidepsin are highly effective in patients with PTCL: a multicenter phase 2 study
Blood · 2021 · 162 citations
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL
Blood · 2011 · 129 citations

OO
Owen O’Connor
35 papers
Lapo Alinari
15 papers · 14 as a fellow
HM
Helen Ma
13 papers · 9 as a fellow
AS
Ahmed Sawas
9 papers
MK
Matko Kalac
9 papers · 7 as a resident
Govind Bhagat
8 papers
JL
Jennifer Lue
8 papers · 2 as a fellow
Changchun Deng
7 papers
Francesca Montanari
7 papers
Jennifer Amengual
7 papers
LF
Lorenzo Falchi
6 papers · 6 as a fellow
LP
Luca Paoluzzi
5 papers · 5 as a resident

Grants

A Randomized, Phase IIB, Multicenter, Trial of Oral Azacytidine Plus Romidepsin Versus Investigator's Choice in Patients with Relapse or Refractory Periperal T-Cell Lymphoma (PTCL).
Food and Drug Administration · R01
PI · $2.4M · University of Virginia
2020–2027

Clinical trials

Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL
Principal investigator · Active not recruiting · Phase 1
University of Virginia
2022–2026
Durvalumab in Different Combinations With Pralatrexate, Romidepsin and Oral 5-Azacitidine for Lymphoma
Principal investigator · Recruiting · Phase 1, Phase 2
University of Virginia
2018–2023
A Global Study of the PETAL Consortium
Site PI · Recruiting
Massachusetts General Hospital
2024–2028